- Home
- TVGN vs RFL Comparison
TVGN vs RFL Comparison
Compare TVGN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- RFL
- Stock Information
- Founded
- TVGN 2020
- RFL 2017
- Country
- TVGN United States
- RFL United States
- Employees
- TVGN N/A
- RFL N/A
- Industry
- TVGN Blank Checks
- RFL Real Estate
- Sector
- TVGN Finance
- RFL Finance
- Exchange
- TVGN Nasdaq
- RFL Nasdaq
- Market Cap
- TVGN 179.0M
- RFL 54.4M
- IPO Year
- TVGN N/A
- RFL N/A
- Fundamental
- Price
- TVGN $0.85
- RFL $1.34
- Analyst Decision
- TVGN Strong Buy
- RFL
- Analyst Count
- TVGN 1
- RFL 0
- Target Price
- TVGN $10.00
- RFL N/A
- AVG Volume (30 Days)
- TVGN 501.6K
- RFL 114.0K
- Earning Date
- TVGN 08-14-2025
- RFL 11-05-2025
- Dividend Yield
- TVGN N/A
- RFL N/A
- EPS Growth
- TVGN N/A
- RFL N/A
- EPS
- TVGN N/A
- RFL N/A
- Revenue
- TVGN N/A
- RFL $732,000.00
- Revenue This Year
- TVGN N/A
- RFL N/A
- Revenue Next Year
- TVGN N/A
- RFL N/A
- P/E Ratio
- TVGN N/A
- RFL N/A
- Revenue Growth
- TVGN N/A
- RFL 35.56
- 52 Week Low
- TVGN $0.26
- RFL $1.28
- 52 Week High
- TVGN $3.09
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- TVGN 34.30
- RFL 39.59
- Support Level
- TVGN $0.84
- RFL $1.31
- Resistance Level
- TVGN $0.99
- RFL $1.51
- Average True Range (ATR)
- TVGN 0.05
- RFL 0.12
- MACD
- TVGN 0.00
- RFL 0.00
- Stochastic Oscillator
- TVGN 3.31
- RFL 14.52
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.